Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Longeveron LLC (LGVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LGVN (1-star) is a SELL. SELL since 4 days. Profits (-53.33%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.39
1 Year Target Price $8.39
| 0 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -91.37% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.46M USD | Price to earnings Ratio 3.02 | 1Y Target Price 8.39 |
Price to earnings Ratio 3.02 | 1Y Target Price 8.39 | ||
Volume (30-day avg) 3 | Beta 0.22 | 52 Weeks Range 0.63 - 2.86 | Updated Date 08/15/2025 |
52 Weeks Range 0.63 - 2.86 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1707.91% |
Management Effectiveness
Return on Assets (TTM) -67.48% | Return on Equity (TTM) -134.52% |
Valuation
Trailing PE 3.02 | Forward PE - | Enterprise Value 21574 | Price to Sales(TTM) 5.53 |
Enterprise Value 21574 | Price to Sales(TTM) 5.53 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA -49.61 | Shares Outstanding 13694600 | Shares Floating 12303298 |
Shares Outstanding 13694600 | Shares Floating 12303298 | ||
Percent Insiders 8.73 | Percent Institutions 6.3 |
Upturn AI SWOT
Longeveron LLC
Company Overview
History and Background
Longeveron Inc. was founded in 2014 and is a clinical stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. The company has focused on developing Lomecel-Bu2122, its investigational allogeneic Mesenchymal Stem Cell (MSC) product.
Core Business Areas
- Cellular Therapy Development: Focuses on developing and commercializing Lomecel-Bu2122, an allogeneic Mesenchymal Stem Cell (MSC) product, for various aging-related and life-threatening conditions.
Leadership and Structure
Longeveron Inc.'s leadership includes key executives in research and development, clinical operations, and finance. The company operates with a functional structure, focusing on research, clinical trials, and commercialization strategies.
Top Products and Market Share
Key Offerings
- Lomecel-Bu2122: Lomecel-Bu2122 is Longeveron's lead investigational product, an allogeneic MSC therapy being developed for aging-related conditions such as Aging Frailty, Alzheimeru2019s Disease, Metabolic Syndrome, and Hypoplastic Left Heart Syndrome (HLHS). Market share data is not publicly available as it is not yet a commercialized product. Key competitors will be other companies working on MSC therapies such as Mesoblast, Athersys, and numerous academic institutions.
Market Dynamics
Industry Overview
The cellular therapy industry is rapidly growing, driven by advances in regenerative medicine and the increasing prevalence of aging-related diseases. It is considered to be an emerging industry with high growth potential. There are no dominant leaders as many therapies are still in early stage clinical trials.
Positioning
Longeveron aims to be a leader in the cellular therapy market, specializing in MSC therapies for aging-related conditions. Its competitive advantage lies in its proprietary Lomecel-Bu2122 product and its focus on specific unmet medical needs.
Total Addressable Market (TAM)
The TAM for aging-related disease therapies is substantial, estimated in the billions of dollars annually. Longeveron is positioned to capture a portion of this market by targeting specific indications with high unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary Lomecel-Bu2122 technology
- Experienced management team
- Focus on unmet medical needs
- Positive clinical trial results
Weaknesses
- Limited financial resources
- Reliance on single product (Lomecel-Bu2122)
- High regulatory hurdles for cellular therapies
- Not yet commercially available (lack of revenue)
Opportunities
- Expanding clinical trials to new indications
- Partnerships with pharmaceutical companies
- Accelerated regulatory pathways (e.g., FDA)
- Increasing awareness of cellular therapies
Threats
- Competition from other cellular therapy companies
- Unfavorable regulatory decisions
- Clinical trial failures
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- MESO
- ATHX
Competitive Landscape
Longeveron competes with other cellular therapy companies. Many small companies each has a very small portion of the market share. The competitive landscape is driven by innovation and clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Growth is characterized by expansion of clinical trials and increasing R&D spending, rather than revenue growth.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include expanding clinical trials for Lomecel-Bu2122 in Alzheimer's and Aging Frailty, and seeking strategic partnerships.
Summary
Longeveron is a clinical-stage biotech company developing cellular therapies. Its strengths lie in its proprietary technology and focus on unmet medical needs. However, it faces weaknesses in limited financial resources and reliance on a single product. Successful clinical trial outcomes and strategic partnerships are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Longeveron LLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2021-02-12 | CEO & Director Mr. Mohamed Wa'el Ahmed Hashad M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://longeveron.com |
Full time employees 25 | Website https://longeveron.com | ||
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.